Uncategorized
Study: Bimatoprost sustained-release implant maintains IOP lowering up to 24 weeks
FORT LAUDERDALE, Fla. — At all dose strengths, a bimatoprost sustained-release implant was well tolerated and comparable to topical bimatoprost in overall IOP reduction, according to 6-month interim results of a phase 1/2 study.“We need something better than eye drops, so we’re all looking for that right way to lower pressure with a sustained delivery device,” E. Randy Craven, MD, said at the American Glaucoma Society meeting.